Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(55)
•••
Post by Ingiboyon Feb 05, 2021 4:22pm
181 Views
Post# 32487491

The Close

The Close
V:RP - REPLICEL LIFE SCIENCES INC - https://www.replicel.com 16:17:29 EST
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
RP - V   0.5 0.41 · 0.49 6.5 0.49 +0.17 53.1 431.4 188 135 0.33  0.55  0.33 0.39  0.10 15:48:54 Jan 25 15 min RT 2¢
TSX-V - V 0.5 0.41 · 0.49 6.5 0.415 +0.095 29.7 306.7 131 78 0.33  0.54  0.33 0.39  0.10 15:43:48   15 min 
NEO ATS - U   0.49 +0.17 53.1 16.0 6 11 0.36  0.55  0.36   15:48:54   15 min 
Alpha - A   0.45 +0.13 40.6 66.5 32 5 0.36  0.55  0.36   15:44:33   15 min 
Omega - O   0.49 +0.17 53.1 5.5 2 5 0.36  0.49  0.36   15:44:25   15 min 
Chi-X - X   0.365 +0.045 14.1 0.5 0 1 0.365  0.365  0.365   11:10:36   15 min 
CX2 - H   0.44 +0.12 37.5 18.8 8 18 0.345  0.55  0.345   15:39:28   15 min 
CXD - D   0.32     0.2 0 1        Jan 21-20   15 min 
TriAct - M   0.32     17.2 7 16        Sep 10 12:40:51   15 min



Depends on what Exchange you want to look at but these all look good to me.  
Good luck to all the longs Monday morning.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities